Clinical approach to the patient with diabetes mellitus and very high insulin requirements

Diabetes Research and Clinical Practice

Volumn 90, Issue 3, 2010, Pages 231-242

  Ovalle, F ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Algorithm; Diabetes; Extreme insulin resistance; High insulin requirement; Insulin; Severe insulin resistance

Indexed keywords

ALPHA INTERFERON; APROTININ; ATYPICAL ANTIPSYCHOTIC AGENT; AZATHIOPRINE; BEZAFIBRATE; CHROMIUM; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GESTAGEN; GLITAZONE DERIVATIVE; GLUCOCORTICOID; GONADORELIN AGONIST; IMMUNOGLOBULIN; INSULIN; LEPTIN; METFORMIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINIC ACID; OMEGA 3 FATTY ACID; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PROTEINASE INHIBITOR; RITUXIMAB; RNA DIRECTED DNA POLYMERASE INHIBITOR; SOMATOMEDIN C; TERBUTALINE; VANADIC ACID;

ALGORITHM; ALLERGIC REACTION; ARTHUS PHENOMENON; CLINICAL TRIAL; CONTINUOUS INFUSION; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; EDEMA; GENETIC DISORDER; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERSENSITIVITY; IMMUNOSUPPRESSIVE TREATMENT; INSULIN ALLERGY; INSULIN CLEARANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; LEPRECHAUNISM; LIPODYSTROPHY; MEDICAL DECISION MAKING; METABOLIC SYNDROME X; PATIENT COMPLIANCE; PLASMAPHERESIS; REVIEW; SIDE EFFECT; WEIGHT GAIN;

ALGORITHMS; AUTOANTIBODIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERGLYCEMIA; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN RESISTANCE; LIPODYSTROPHY; MALE; PATIENT COMPLIANCE; RECEPTOR, INSULIN;

EID: 78649475437     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.06.025     Document Type: Review

References (77)

1. Cowie C.C., Rust K.F., Ford E.S., Eberhardt M.S., Byrd-Holt D.D., Li C., et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009, 32:287-294.
2. Mann D.M., Woodward M., Ye F., Krousel-Wood M., Muntner P. Trends in medication use among US adults with diabetes mellitus: glycemic control at the expense of controlling cardiovascular risk factors. Arch Intern Med 2009, 169:1718-1720.
3. Himsworth H.P. Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types. The Lancet 1936, 227:127-130.
4. MacBryde C.M. Insulin resistance in diabetes mellitus. Arch Intern Med 1933, 52:932-944.
5. Insulin resistance: the clinical spectrum 1995, Mosby, St. Louis. C. Mantzoros, J. Flier (Eds.).
6. American Diabetes Association Consensus development conference on insulin resistance. Diabetes Care 1998, 21:310-314.
7. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
8. DeFronzo R.A., Hendler R., Simonson D. Insulin resistance is a prominent feature of insulin-dependent diabetes. Diabetes 1982, 31:795-801.
9. Olefsky J.M., Revers R.R., Prince M., Henry R.R., Garvey W.T., Scarlett J.A., et al. Insulin resistance in non-insulin dependent (type II) and insulin dependent (type I) diabetes mellitus. Adv Exp Med Biol 1985, 189:176-205.
10. Cochran E. U-500 insulin: when more with less yields success. Diabetes Spectrum 2009, 22:116-122.
11. Cochran E., Musso C., Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care 2005, 28:1240-1244.
12. Crasto W., Jarvis J., Hackett E., Nayyar V., McNally P.G., Davies M.J., et al. Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. Postgrad Med J 2009, 85:219-222.
13. Lane W.S., Cochran E.K., Jackson J.A., Scism-Bacon J.L., Corey I.B., Hirsch I.B., et al. High-dose insulin therapy: is it time for U-500 insulin?. Endocr Pract 2009, 15:71-79.
14. Vidal-Puig A., Moller D. Insulin resistance: classification, prevalence, clinical manifestations, and diagnosis. Androgen excess disorders in women 1997, 227-236. Lippincott Raven, Philadelphia. R. Azziz, J. Nestler, D. Dewailly (Eds.).
15. Kahn C.R., Flier J.S., Bar R.S., Archer J.A., Gorden P., Martin M.M., et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med 1976, 294:739-745.
16. Tritos N.A., Mantzoros C.S. Clinical review 97: syndromes of severe insulin resistance. J Clin Endocrinol Metab 1998, 83:3025-3030.
17. Mendenhall E.N. Tumor of the pineal body with high insulin resistance. J Indiana State Med Assoc 1950, 43:32-36. illust.
18. Rabson S.M., Mendenhall E.N. Familial hypertrophy of pineal body, hyperplasia of adrenal cortex and diabetes mellitus; report of 3 cases. Am J Clin Pathol 1956, 26:283-290.
19. Donohue W.L., Uchida I. Leprechaunism: a euphemism for a rare familial disorder. J Pediatr 1954, 45:505-519.
20. Moller D.E., Flier J.S. Insulin resistance-mechanisms, syndromes, and implications. N Engl J Med 1991, 325:938-948.
21. Arioglu E., Andewelt A., Diabo C., Bell M., Taylor S.I., Gorden P. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore) 2002, 81:87-100.
22. Flier J.S., Eastman R.C., Minaker K.L., Matteson D., Rowe J.W. Acanthosis nigricans in obese women with hyperandrogenism. Characterization of an insulin-resistant state distinct from the type A and B syndromes. Diabetes 1985, 34:101-107.
23. Globerman H., Karnieli E. Analysis of the insulin receptor gene tyrosine kinase domain in obese patients with hyperandrogenism, insulin resistance and acanthosis nigricans (type C insulin resistance). Int J Obes Relat Metab Disord 1998, 22:349-353.
24. Hashimoto N., Makino H. Type C insulin resistance. Nippon Rinsho 1994, 52:2637-2640.
25. Nakamura F., Taira M., Hashimoto N., Makino H., Sasaki N. Familial type C syndrome of insulin resistance and short stature with possible autosomal dominant transmission. Endocrinol Jpn 1989, 36:349-358.
26. Pandit M.K., Burke J., Gustafson A.B., Minocha A., Peiris A.N. Drug-induced disorders of glucose tolerance. Ann Intern Med 1993, 118:529-539.
27. Schneider A., Bennett R. Impaired absorption of insulin as a cause insulin resistance. Diabetes 1975, 24:443.
28. Paulsen E.P., Courtney J.W., Duckworth W.C. Insulin resistance caused by massive degradation of subcutaneous insulin. Diabetes 1979, 28:640-645.
29. Schade D.S., Duckworth W.C. In search of the subcutaneous-insulin-resistance syndrome. N Engl J Med 1986, 315:147-153.
30. Krentz A.J. Insulin resistance. BMJ 1996, 313:1385-1389.
31. O'Brien I.A., Lewin I.G., Frier B.M., Rodman H., Genuth S., Corrall R.J. Factitious diabetic instability. Diabet Med 1985, 2:392-394.
32. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004, 350:1220-1234.
33. Hegele R.A. Monogenic forms of insulin resistance: apertures that expose the common metabolic syndrome. Trends Endocrinol Metab 2003, 14:371-377.
34. Savage D.B., Semple R.K., Chatterjee V.K., Wales J.K., Ross R.J., O'Rahilly S. A clinical approach to severe insulin resistance. Endocr Dev 2007, 11:122-132.
35. Flier J.S., Moller D.E., Moses A.C., O'Rahilly S., Chaiken R.L., Grigorescu F., et al. Insulin-mediated pseudoacromegaly: clinical and biochemical characterization of a syndrome of selective insulin resistance. J Clin Endocrinol Metab 1993, 76:1533-1541.
36. Paisey R.B., Carey C.M., Bower L., Marshall J., Taylor P., Maffei P., et al. Hypertriglyceridaemia in Alstrom's syndrome: causes and associations in 37 cases. Clin Endocrinol (Oxf) 2004, 60:228-231.
37. Fernandez-Real J.M., Molina A., Broch M., Ricart W., Gutierrez C., Casamitjana R., et al. Tumor necrosis factor system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy. Diabetes 1999, 48:1108-1112.
38. Savkur R.S., Philips A.V., Cooper T.A. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 2001, 29:40-47.
39. Vestergaard H., Klein H.H., Hansen T., Muller J., Skovby F., Bjorbaek C., et al. Severe insulin-resistant diabetes mellitus in patients with congenital muscle fiber type disproportion myopathy. J Clin Invest 1995, 95:1925-1932.
40. Uotani S., Yamaguchi Y., Yokota A., Yamasaki H., Takino H., Chikuba N., et al. Molecular analysis of insulin receptor gene in Werner's syndrome. Diabetes Res Clin Pract 1994, 26:171-176.
41. Uriuhara A., Morita S., Kuroda S., Fumoto M., Araki S., Aoyama N., et al. Severe insulin-resistant diabetes mellitus associated with hypereosinophilic syndrome. Intern Med 1994, 33:632-636.
42. Greenfield J.R., Tuthill A., Soos M.A., Semple R.K., Halsall D.J., Chaudhry A., et al. Severe insulin resistance due to anti-insulin antibodies: response to plasma exchange and immunosuppressive therapy. Diabet Med 2009, 26:79-82.
43. Mizuhashi S., Nakamura K., Mori Y., Noda M., Nakanishi K. Insulin allergy and immunologic insulin resistance caused by interleukin-6 in a patient with lung cancer. Diabetes Care 2006, 29:1711-1712.
44. Darmon P., Castera V., Koeppel M.-C., Petitjean C., Dutour A. Type III allergy to insulin detemir. Diabetes Care 2005, 28:2980-12980.
45. Chen D., Misra A., Garg A. Lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 2002, 87:4845-4856.
46. Williams G., Pickup J.C., Keen H. Massive insulin resistance apparently due to rapid clearance of circulating insulin. Am J Med 1987, 82:1247-1252.
47. Lane W.S. Use of U-500 regular insulin by continuous subcutaneous insulin infusion in patients with type 2 diabetes and severe insulin resistance. Endocr Pract 2006, 12:251-256.
48. Binder C. Absorption of injected insulin. A clinical-pharmacological study. Acta Pharmacol Toxicol (Copenh) 1969, 27(Suppl. 2):1-84.
49. Haque W.A., Shimomura I., Matsuzawa Y., Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 2002, 87:2395.
50. Semple R.K., Cochran E.K., Soos M.A., Burling K.A., Savage D.B., Gorden P., et al. Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin resistance. Diabetes Care 2008, 31:977-979.
51. Semple R.K., Halberg N.H., Burling K., Soos M.A., Schraw T., Luan J., et al. Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies. Diabetes 2007, 56:1712-1717.
52. Semple R.K., Soos M.A., Luan J., Mitchell C.S., Wilson J.C., Gurnell M., et al. Elevated plasma adiponectin in humans with genetically defective insulin receptors. J Clin Endocrinol Metab 2006, 91:3219-3223.
53. Mao C.S., Riegelhuth M.E., Van Gundy D., Cortez C., Melendez S., Ipp E. An overnight insulin infusion algorithm provides morning normoglycemia and can be used to predict insulin requirements in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997, 82:2466-2470.
54. Musso C., Cochran E., Moran S.A., Skarulis M.C., Oral E.A., Taylor S., et al. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore) 2004, 83:209-222.
55. Cochran E., Young J.R., Sebring N., DePaoli A., Oral E.A., Gorden P. Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson-Mendenhall syndrome. J Clin Endocrinol Metab 2004, 89:1548-1554.
56. Yauger B.J., Gorden P., Park J., Cochran E., Stratton P. Effect of depot medroxyprogesterone acetate on glucose tolerance in generalized lipodystrophy. Obstet Gynecol 2008, 112:445-447.
57. Garg R., Johnston V., McNally P.G., Davies M.J., Lawrence I.G. U-500 insulin: why, when and how to use in clinical practice. Diabetes Metab Res Rev 2007, 23:265-268.
58. Lalej-Bennis D., Selam J.L., Fluteau-Nadler S., M'Bemba J., Reach G., Sorel G., et al. Extreme insulin resistance: clinical management by external subcutaneous insulin infusion. Diabetes Metab 1997, 23:533-536.
59. Riveline J.P., Vantyghem M.C., Fermon C., Brunet C., Gautier J.F., Renard E., et al. Subcutaneous insulin resistance successfully circumvented on long term by peritoneal insulin delivery from an implantable pump in four diabetic patients. Diabetes Metab 2005, 31:496-498.
60. Soudan B., Girardot C., Fermon C., Verlet E., Pattou F., Vantyghem M.C. Extreme subcutaneous insulin resistance: a misunderstood syndrome. Diabetes Metab 2003, 29:539-546.
61. Dandona P. Low-dose insulin infusions in diabetic patients with high insulin requirements. Lancet 1978, 2:637.
62. Dandona P., Foster M., Healey F., Greenbury E., Beckett A.G. Low-dose insulin infusions in diabetic patients with high insulin requirements. Lancet 1978, 2:283-285.
63. Page K.A., Dejardin S., Kahn C.R., Kulkarni R.N., Herold K.C., Inzucchi S.E. A patient with type B insulin resistance syndrome, responsive to immune therapy. Nat Clin Pract Endocrinol Metab 2007, 3:835-840.
64. Eriksson J.W., Bremell T., Eliasson B., Fowelin J., Fredriksson L., Yu Z.W. Successful treatment with plasmapheresis, cyclophosphamide, and cyclosporin A in type B syndrome of insulin resistance. Case report. Diabetes Care 1998, 21:1217-1220.
65. Coll A.P., Thomas S., Mufti G.J. Rituximab therapy for the type B syndrome of severe insulin resistance. N Engl J Med 2004, 350:310-311.
66. Segal T., Webb E., Viner R., Pusey C., Wild G., Allgrove J. Severe insulin resistance secondary to insulin antibodies: successful treatment with the immunosuppressant MMF. Pediatr Diabetes 2008, 9:250-254.
67. Ellis M.F. Severe insulin resistance treated with plasmapheresis: case report and discussion. Am J Crit Care 1994, 3:460-463.
68. Chong A., Lupsa B., Cochran E., Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 2010, 53:27-35.
69. Javor E.D., Cochran E.K., Musso C., Young J.R., Depaoli A.M., Gorden P. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 2005, 54:1994-2002.
70. McDonald A., Williams R.M., Regan F.M., Semple R.K., Dunger D.B. IGF-I treatment of insulin resistance. Eur J Endocrinol 2007, 157(Suppl. 1):S51-S56.
71. Hussain M.A., Froesch E.R. Treatment of type A insulin resistance with insulin-like growth factor-I. Lancet 1993, 341:1536-1537.
72. van Alfen-van der Velden A.A., Noordam C., de Galan B.E., Hoorweg-Nijman J.J., Voorhoeve P.G., Westerlaken C. Successful treatment of severe subcutaneous insulin resistance with inhaled insulin therapy. Pediatr Diabetes 2009, 10.1111/j.1399-5448.2009.00597.x.
73. Brossard J.H., Havrankova J., Rioux D., Bertrand S., D'Amour P. Long-term use of intramuscular insulin therapy in a type I diabetic patient with subcutaneous insulin resistance. Diabet Med 1993, 10:174-176.
74. Azziz R. The hyperandrogenic-insulin-resistant acanthosis nigricans syndrome: therapeutic response. Fertil Steril 1994, 61:570-572.
75. Elkind-Hirsch K.E., Valdes C.T., Malinak L.R. Insulin resistance improves in hyperandrogenic women treated with Lupron. Fertil Steril 1993, 60:634-641.
76. Pickup J.C., Bilous R.W., Keen H. Aprotinin and insulin resistance. Lancet 1980, 2:93-94.
77. Via M., Scurlock C., Raikhelkar J., Di Luozzo G., Mechanick J.I. Chromium infusion reverses extreme insulin resistance in a cardiothoracic ICU patient. Nutr Clin Pract 2008, 23:325-328.